eFlow®rapid Nebuliser System is an efficient device for the treatment of respiratory diseases. During development, special care was taken to develop an efficient, safe and fast inhalation treatment with the following characteristics:
Item No.: 178G1005
The eFlow®rapid nebuliser system provides you with an efficient device for the treatment of respiratory diseases. In this video, we introduce you to the most important components and functions of the eFlow®rapid Inhalation System.
Instructions for use
Instructions for use
178D1007-C-04/18
Product information for users
eFlow®rapid nebuliser system
470.01 KB Download PDFAerosol characteristics of the eFlow®rapid Nebuliser System
| Total Output Rate: | 610 mg/min |
| MMD: | 4,1 µm |
| Mass percentage below 5 µm: | 69 % |
Measurement with laser diffraction (Helos Sympa-Tec) at 23°C and 50% relative humidity. Nebulised medium: 0.9% NaCl (4ml). Inspiratory flow: 20l/min. May vary depending on medication and aerosol generator used.
Technical data
| Nebuliser principle: | Perforated vibrating membrane |
| Oscillating frequency: | 117 kHz |
Operation with a regular or rechargeable battery:
At least 90 min. Operation with a fully charged rechargeable battery.
| Power adapter: | |
| Alternating current: | 100 - 240V, 50/60 Hz |
| Weight of nebuliser: | ~ 55 g |
| Total weight: | ~ 300 g |
| Min. fill volume: | 2.0 ml |
| Max. fill volume: | 6.0 ml |
Spare parts: All spare parts are available from your dealer or a chemist. In all other countries, PARI items can be obtained through our PARI agents in the respective country.
Electromagnetic compatibility - Guidance and manufacturer's declaration IEC 60601-1-2: Edition 4.0; 2014-02
231.01 KB Download PDF1Compared to PARI LC Plus® nebulizer; D Hubert. S Leroy, S Dominique, J Kovarik: Pharmakokinetik comparison of inhaled tobramycin (TOBI®) via PARI eFlow®rapid or PARI LC Plus™ nebulizers in cystic fibrosis patients. European Cystic Fibrosis Society, 30th Cystic Fibrosis Conference, Belek, Antalya-Turkey, 13-16 June 2007
2 Govoni et al. 2013, Pulm.Phar. Ther 26 (2013)249-255
© 2020 PARI GmbH Spezialisten für effektive Inhalation
